Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Most humans have long-lived infections in various tissues—including in the nervous system—that typically do not result in ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Researchers show that the immune system can recognize and control the latent stage of the parasite Toxoplasma gondii, a finding that can inform the study of latency in other infections of the nervous ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...

every 12 hSevere CMV disease, GI disease, pneumonia, CNS disease: Ganciclovir 5 mg/kg iv. every 12 hGanciclovir-resistant CMV disease: Foscarnet 60 mg/kg iv. every 8 h or 90 mg/kg iv. every 12 h ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

Board member Mick Hitchcock, named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...